文献速递肝病

囊性纤维化相关肝病:CFTR调节剂时代的临床表现、诊断与监测

Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies.
PubMed 文献 · J Hepatol · 2021-10-20

囊性纤维化相关肝病(CFLD)由胆管上皮细胞CFTR缺陷所致,需与其他无病理意义的肝脏表现区分。主要组织学表现为局灶性胆汁性纤维化,约10%病例进展为门脉高压,儿童期可发展为多小叶性肝硬化,成人可见非肝硬化性门脉高压。本文综述其表型特征、病理生理及以影像为重点的诊断随访方法。

要点

  • CFLD需与其他无病理意义的肝脏表现鉴别,主要组织学为局灶性胆汁性纤维化。
  • 约10%病例出现门脉高压,儿童期多由局灶性胆汁性纤维化进展为多小叶性肝硬化所致。
  • 成人非肝硬化性门脉高压(门窦血管病所致)识别率增加,需与肝硬化性门脉高压区分。

核心结论

  • CFLD由胆管上皮细胞CFTR缺陷致病,临床与组织学表现多样,需精确分类以评估CFTR调节剂对肝脏的影响。

研究设计与样本

  • 综述,讨论CFLD的表型特征、病理生理及以影像为重点的诊断与随访方法。

主要发现

  • CFLD主要组织学表现为局灶性胆汁性纤维化,通常无症状。
  • 约10%病例出现门脉高压,儿童期多因局灶性胆汁性纤维化进展为多小叶性肝硬化。
  • 非肝硬化性门脉高压由门窦血管病所致,主要在年轻成人中识别率增加。

临床怎么用

  • 需先精确分类肝胆受累谱,再评估CFTR调节剂对肝脏的影响。
  • 门脉高压少数病例需特定管理,包括终末期肝病行肝移植。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cystic fibrosis (CF) is the most common autosomal recessive disease in the Caucasian population. Cystic fibrosis-related liver disease (CFLD) is defined as the pathogenesis related to the underlying CFTR defect in biliary epithelial cells. CFLD needs to be distinguished from other liver manifestations that may not have any pathological significance. The clinical/histological presentation and severity of CFLD vary. The main histological presentation of CFLD is focal biliary fibrosis, which is usually asymptomatic. Portal hypertension develops in a minority of cases (about 10%) and may require specific management including liver transplantation for end-stage liver disease. Portal hypertension is usually the result of the progression of focal biliary fibrosis to multilobular cirrhosis during childhood. Nevertheless, non-cirrhotic portal hypertension as a result of porto-sinusoidal vascular disease is now identified increasingly more frequently, mainly in young adults. To evaluate the effect of new CFTR modulator therapies on the liver, the spectrum of hepatobiliary involvement must first be precisely classified. This paper discusses the phenotypic features of CFLD, its underlying physiopathology and relevant diagnostic and follow-up approaches, with a special focus on imaging.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Dana J, Debray D, Beaufrère A, et al. Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies. J Hepatol. 2021. PMID: 34678405. doi:10.1016/j.jhep.2021.09.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。